Jump to navigation Jump to search
Tibolone Structural Formulae V.1.png
Clinical data
AHFS/Drugs.comInternational Drug Names
  • ADEC Category D
Routes of
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass312.446 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Tibolone


Most recent articles on Tibolone

Most cited articles on Tibolone

Review articles on Tibolone

Articles on Tibolone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tibolone

Images of Tibolone

Photos of Tibolone

Podcasts & MP3s on Tibolone

Videos on Tibolone

Evidence Based Medicine

Cochrane Collaboration on Tibolone

Bandolier on Tibolone

TRIP on Tibolone

Clinical Trials

Ongoing Trials on Tibolone at Clinical Trials.gov

Trial results on Tibolone

Clinical Trials on Tibolone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tibolone

NICE Guidance on Tibolone


FDA on Tibolone

CDC on Tibolone


Books on Tibolone


Tibolone in the news

Be alerted to news on Tibolone

News trends on Tibolone


Blogs on Tibolone


Definitions of Tibolone

Patient Resources / Community

Patient resources on Tibolone

Discussion groups on Tibolone

Patient Handouts on Tibolone

Directions to Hospitals Treating Tibolone

Risk calculators and risk factors for Tibolone

Healthcare Provider Resources

Symptoms of Tibolone

Causes & Risk Factors for Tibolone

Diagnostic studies for Tibolone

Treatment of Tibolone

Continuing Medical Education (CME)

CME Programs on Tibolone


Tibolone en Espanol

Tibolone en Francais


Tibolone in the Marketplace

Patents on Tibolone

Experimental / Informatics

List of terms related to Tibolone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Tibolone is a synthetic steroid hormone drug, which is fairly non-selective in its binding profile, acting as an agonist mainly at estrogen receptors, with a preference for ER alpha.[1] It is used mainly for treatment of endometriosis,[2] as well as hormone replacement therapy in post-menopausal women. Tibolone has similar or greater efficacy compared to older hormone replacement drugs, but shares a similar side effect profile.[3][4][5] It has also been investigated as a possible treatment for female sexual dysfunction.[6]

Adverse effects

A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects.[7]


  1. Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (August 2009). "Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites". The Journal of Steroid Biochemistry and Molecular Biology. 116 (1–2): 8–14. doi:10.1016/j.jsbmb.2009.03.008. PMID 19464167.
  2. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A (2009). Al Kadri, Hanan, ed. "Hormone therapy for endometriosis and surgical menopause". Cochrane Database of Systematic Reviews (Online) (1): CD005997. doi:10.1002/14651858.CD005997.pub2. PMID 19160262.
  3. Lazovic G, Radivojevic U, Marinkovic J (April 2008). "Tibolone: the way to beat many a postmenopausal ailments". Expert Opinion on Pharmacotherapy. 9 (6): 1039–47. doi:10.1517/14656566.9.6.1039. PMID 18377345.
  4. Garefalakis M, Hickey M (2008). "Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence". Clinical Interventions in Aging. 3 (1): 1–8. PMC 2544356. PMID 18488873.
  5. Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN (2009). "Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists". European Journal of Gynaecological Oncology. 30 (1): 82–4. PMID 19317264.
  6. Ziaei, S; Moghasemi, M; Faghihzadeh, S (2010). "Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women". Climacteric : the journal of the International Menopause Society. 13 (2): 147–56. doi:10.1080/13697130903009195. PMID 19731119.
  7. "Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says". U.S. Department of Health & Human Services - Agency for Healthcare Research and Quality. September 2009. Retrieved 2 June 2014.